Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Transfected Stable Cell Lines
Reliable | High-Performance | Wide Rage
Precision reporter, kinase, immune receptor, biosimilar, Cas9, and knockout stable cell lines for diverse applications.
Premade Virus Particles
Ready-to-Use | High Titer | Versatile Applications
Premade AAV, adenovirus, lentivirus particles, safe, stable, in stock.
Virus-Like Particles (VLPs)
Stable | Scalable | Customizable
Advanced VLPs for vaccine development (Chikungunya, Dengue, SARS-CoV-2), gene therapy (AAV1 & AAV9), and drug screening (SSTR2, CCR5).
Oligonucleotide Products
Precise | High Yield | Tailored Solutions
Accelerate your research with cost-effective LncRNA qPCR Array Technology.
RNA Interference Products
Targeted | Potent | High Specificity
Human Druggable Genome siRNA Library enables efficient drug target screening.
Recombinant Drug Target Proteins
Authentic | Versatile | Accelerated
Providing functional, high-purity recombinant proteins—including membrane proteins and nanodiscs—to overcome bottlenecks in drug screening and target validation.
Clones
Validated | Reliable | Comprehensive Collection
Ready-to-use clones for streamlined research and development.
Kits
Complete | Convenient | High Sensitivity
Chromogenic LAL Endotoxin Assay Kit ensures precise, FDA-compliant endotoxin quantification for biosafety testing.
Enzymes
Purified | Stable | Efficient
Powerful Tn5 Transposase for DNA insertion and random library construction.
Aptamers
Highly Specific | Robust | Versatile
Aptamers for key proteins like ACVR1A, Akt, EGFR, and VEGFR.
Adjuvants
Enhancing | Synergistic | Effective
Enhance immune responses with high-purity, potent CpG ODNs.
Laboratory Equipment
Innovative | Reliable | High-Precision
Effortlessly streamline DNA extraction with CB™ Magnetic-Nanoparticle Systems.
Stable Cell Line Generation
Reliable | Scalable | Customizable
Fast proposals, regular updates, and detailed reports; strict quality control, and contamination-free cells; knockout results in 4-6 weeks.
Target-based Drug Discovery Service
Innovative | Comprehensive | Efficient
Target identification, validation, and screening for drug discovery and therapeutic development.
Custom Viral Service
Versatile | High-Yield | Safe
Unbeatable pricing, fully customizable viral packaging services (covering 30,000+ human genes, 200+ mammals, 50+ protein tags).
Custom Antibody Service
Precise | Flexible | Efficient
End-to-end antibody development support, from target to validation, enabling clients to rapidly obtain application-ready antibodies.
Antibody-Drug Conjugation Service
Integrated | Controlled | Translational
Comprehensive solutions covering design, development, and validation to ensure conjugated drugs with consistent quality and clinical potential.
Protein Degrader Service
Efficient | High-Precision | Advanced Therapeutics
Harness the power of protein degraders for precise protein degradation, expanding druggable targets and enhancing therapeutic effectiveness for cutting-edge drug discovery.
Nucleotides Service
Accurate | Flexible | High-Quality
Custom synthesis of oligonucleotides, primers, and probes for gene editing, PCR, and RNA studies.
Custom RNA Service
Custom RNA ServicePrecise | Flexible | GMP-ReadyCustom
RNA design, synthesis, and manufacturing—covering mRNA, saRNA, circRNA, and RNAi. Fast turnaround, rigorous QC, and seamless transition from research to GMP production.
Custom Libraries Construction Service
Comprehensive | High-throughput | Accurate
Custom cDNA, genomic, and mutagenesis libraries for drug discovery, screening, and functional genomics.
Gene Editing Services
Precise | Efficient | Targeted
Gene editing solutions for gene editing, knockouts, knock-ins, and customized genetic modifications. Integrated multi-platform solutions for one-stop CRISPR sgRNA library synthesis and gene screening services
Microbe Genome Editing Service
Precise | Scalable | Customizable
Enhance microbial productivity with advanced genome editing using Rec-mediated recombination and CRISPR/Cas9 technologies.
Biosafety Testing Service
Reliable | Comprehensive | Regulated
Complete biosafety testing solutions for gene therapy, viral vectors, and biologics development.
Plant Genetic Modification Service
Advanced | Sustainable | Tailored
Genetic modification for crop improvement, biotechnology, and plant-based research solutions.
Plant-based Protein Production Service
Efficient | Scalable | Customizable
Plant-based protein expression systems for biopharmaceuticals, enzyme production, and research.
Aptamers Service
Innovative | Fast | Cost-Effective
Revolutionizing drug delivery and diagnostic development with next-generation high-throughput aptamer selection and synthesis technologies.
CGT Biosafety Testing
Comprehensive | Accurate | Regulatory-compliant
Internationally certified evaluation system for biologics, gene therapies, nucleic acid drugs, and vaccines.
Pandemic Detection Solutions
Rapid | Precise | Scalable
Balancing accuracy, accessibility, affordability, and rapid detection to safeguard public health and strengthen global response to infectious diseases.
cGMP Cell Line Development
Reliable | Scalable | Industry-leading
Stable expression over 15 generations with rapid cell line development in just 3 months.
Supports adherent and suspension cell lines, offering MCB, WCB, and PCB establishment.
GMP mRNA Production
Efficient | Scalable | Precise
Scalable mRNA production from milligrams to grams, with personalized process design for sequence optimization, cap selection, and nucleotide modifications, all in one service.
GMP Plasmid Production
High Quality | Scalable | Regulatory-compliant
Our plasmid production services span Non-GMP, GMP-Like, and GMP-Grade levels, with specialized options for linearized plasmids.
GMP Viral Vector Manufacturing
Scalable | High Yield | Quality-driven
Advanced platforms for AAV, adenovirus, lentivirus, and retrovirus production, with strict adherence to GMP guidelines and robust quality control.
AI-Driven Gene Editing and Therapy
Innovative | Precision | Transformative
AI-powered one-click design for customized CRISPR gene editing strategy development.
AI-Antibody Engineering Fusion
Next-Generation | Targeted | Efficient
AI and ML algorithms accelerate antibody screening and predict new structures, unlocking unprecedented possibilities in antibody engineering.
AI-Driven Enzyme Engineering
Smart | Efficient | Tailored
High-throughput enzyme activity testing with proprietary datasets and deep learning models for standardized and precise enzyme engineering design.
AI-Enhanced Small Molecule Screening
Predictive | Efficient | Insightful
Leverage AI to uncover hidden high-potential small molecules, prioritize leads intelligently, and reduce costly trial-and-error in early drug discovery.
AI-Driven Protein Degrader Drug Development
Innovative | Targeted | Accelerated
Use AI-guided design to optimize protein degraders, addressing design complexity and enhancing efficacy while shortening development timelines.
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
| Cat.No. | Product Name | Price |
|---|
Ewing sarcoma breakpoint region 1 gene (EWSR1) is a member of the TET family, which includes three molecules, FUS/TLS, EWSR1 and TAF15, all of which belong to RNA-binding proteins. TET family proteins are expressed in various tissues. Because they possess a nuclear localization sequence, they are mainly located in the nucleus, but may also be translocated into the cytosol under stress or pathological conditions. Both TET family proteins have a transcriptional activation domain and an RNA binding domain and contain multiple conserved structures such as serine-tyrosine-glycine-glutamine domain (SYGQ), RNA recognition motif (RRM), zinc finger motif, arginine-glycine-glycine rich region (RGG) and the like. In addition to direct binding to RNA, TET family proteins can also bind to DNA, and can also act as transcriptional cofactors to directly bind to transcription factors, including biological processes including gene expression regulation, mRNA splicing editing, signal pathway regulation, and DNA repair.
The researchers identified another translocation of the EWSR1 gene in soft tissue malignant melanoma, which consists of the N-terminal domain of EWSR1 and the bZIP domain of the transcription factor ATF-1. In addition, the EWSR1 gene can also form tumor-specific fusion protein transcription factors with a variety of transcription factors such as ERG, NR4A3, and CHOP. The common feature of these EWSR1 fusion proteins is that the N-terminal transcriptional activation domain of EWSR1 is fused to the DNA-binding domain of the C-terminus of a transcription factor, thereby enabling DNA binding activity and transcriptional regulation. These fusion proteins have a strict relationship with tumor types and are thought to play a key role in the pathogenesis and formation of tumors.
However, in a tumor expressing an EWSR1 fusion protein, only one allele translocation occurs, and the other allele still expresses EWSR1. This suggests that in addition to chromosomal ectopic, EWSR1 may also play a role in tumorigenesis through other mechanisms.
EWSR1 Gene Break and Tumor
Ewing's sarcoma is the second most common osteosarcoma in children and young adults, including Ewing's sarcoma/primary neuroectodermal tumors. It also includes primitive neuroectodermal tumors, Aslan tumors, olfactory neuroblastoma, malignant interstitial tumors and extra-orbital Ewing sarcoma, a group of blues chroma cell tumor with the same histological and molecular characteristics present in bone and soft tissue. Most cases occur in the soft tissues of the vertebrae and proximal extremities, and can also occur in the internal organs such as the kidney, pancreas, and meninges. Ewing sarcoma can occur at any age, and more than 90% of Ewing's sarcoma undergo translocation of EWSR1 and ETS family genes FLI1 and ERG. The fusion proteins formed by these translocations can target genes involved in cell growth, proliferation, senescence, and tumorigenesis, thereby altering the fate of cells, leading to abnormal proliferation and producing different types of tumors. Therefore, research on the function of EWSR1 mainly focuses on the process of forming fusion proteins with various transcription factor translocations to participate in the development of malignant tumors. The sequence encoding the RNA-binding domain of the EWSR1 gene and the sequence encoding the DNA-binding domain of the FLI1 gene translocate, thereby changing the open reading frame of the EWSR1 gene on chromosome 22.
Figure 1. The influence of EWSR1-ETS fusion protein at the transcriptome level. (Sand, et al. 2015)
Approximately 85% of Ewing's sarcoma cytogenetics have at(11;22)(q24;q12) translocation leading to the EWSR1-FLI1 fusion gene, which plays an important transcription factor in Ewing's sarcoma. The prognosis of patients with Ewing sarcoma is related to the clinical stage, location and tumor size of the tumor, as well as TP53 status, CDKN2A deletion, telomerase expression, and chromosome 1q acquisition. The type of EWSR1-ETS gene fusion is less related to the prognosis of patients with Ewing's sarcoma. However, it should be noted that the EWSR1 gene break can also occur in the following soft tissue tumors. In addition, EWSR1 gene breaks can also occur in non-soft tissue tumors, including acute myeloid leukemia, granulocyte sarcoma, and acute B lymphoblastic leukemia. Cao et al. reported that 1 case of parental plasmacytoid dendritic cell tumor also had EWSR1 gene break. Recently, it has been reported in the literature that EWSR1 gene breaks are also common in papillary thyroid carcinoma and thyroid carcinoma with Ewing sarcoma family tumor components.
A characteristic cytogenetic abnormality of mucin-like liposarcoma is that the t(12;16) (q13;p11) translocation results in a FUS-DDIT3 (CHOP) fusion gene, and more than 95% of mucinous liposarcomas have the fusion gene. The fusion gene is a highly sensitive and specific molecular marker of mucin-like liposarcoma, while other tumors of similar morphology, including mucosal hyperdifferentiation/dedifferentiated liposarcoma and mucinous fibrosarcoma, lack the fusion gene. At present, there is insufficient evidence to support the existence of mixed mucinous liposarcoma and dedifferentiated liposarcoma. A few t(12;22) (q13;q12) translocations result in the EWSR1-DDIT3 fusion gene.
Gastrointestinal malignant neuroectodermal tumor: This tumor was named early in the "gastrointestinal clear cell sarcoma", "gastrointestinal clear cell sarcomatoid tumor" and the like. The study reported 16 cases of this tumor, which is considered to be an independent tumor with neuroectodermal differentiation characteristics and lack of melanin phenotype, and was named "gastrointestinal malignant neuroectodermal tumor". Most gastrointestinal malignant neuroectodermal tumors have an EWSR1-ATF1 or EWSR1-CREB1 fusion gene.
References:
Contact us today for a free consultation with the scientific team and discover how Creative Biogene can be a valuable resource and partner for your organization.
Inquiry
Copyright © Creative Biogene. All rights reserved.